DataMEDS AI Unveils New Corporate Website
DataMEDS AI connects a refreshed AI-focused brand and website to prior debt reduction, share retirement and an AI diagnostics lab acquisition.
Rhea-AI Summary
DataMEDS AI (MEDS) launched its new corporate website, www.DataMedsAI.com, following recent balance-sheet and business changes announced earlier in 2026.
The company previously acquired Helomics Corporation's AI Cancer Diagnostics Lab from Axe Compute and settled litigation related to the May 11, 2023 acquisition of Wellgistics, LLC. The settlement resulted in the extinguishment of approximately $19 million in liabilities and the retirement of 364,099 common shares. Interim Co-CEO Gerald E. Commissiong said the company is preparing to soft launch its Health Lives Here consumer application as part of a refreshed, AI‑centric marketing and branding strategy.
Positive
- Litigation settlement eliminated approximately $19 million in liabilities
- Settlement led to retirement of 364,099 common shares
- Acquisition of Helomics AI Cancer Diagnostics Lab expands cancer diagnostics capabilities
Negative
- None.
Key Terms
smart contracts technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL / ACCESS Newswire / September 21, 2026 / DataMEDS AI, Inc. (NASDAQ:MEDS) (the "Company" or "DataMEDS"), a Health IT company vertically integrating health data acquisition and transfer, today announced that it launched its new corporate website www.DataMedsAI.com.
This change comes following the recent announcement that DataMEDS has acquired Helomics Corporation's artificial intelligence (AI) Cancer Diagnostics Lab from Axe Compute, and that the Company settled outstanding litigation that resulted in the extinguishment of ~
"With the previously disclosed closing of the Helomics Corporation acquisition and settlement of litigation related to the May 11, 2023 acquisition of Wellgistics, LLC., we are now poised to launch our Health Lives Here consumer application as we begin telling the DataMEDS story to the broader market," said Gerald E. Commissiong, Interim Co-CEO of DataMEDS. "Our new corporate website represents the parent company's new branding. We have retooled our marketing efforts to be AI-centric so that we are able to get organic traction online as we begin to draw earned media interest in our story. We intend to soft launch the Health Lives Here app in short order."
About DataMEDS AI, Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS) (formerly Wellgistics Health, Inc.) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMEDS AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: future events, including an increase in organic traffic to the Company's website and the ability of the Company to acquire earned media interest. These statements are based on management's current expectations and are not predictions of actual performance; the Company's plans to expand into telemedicine and diagnostic laboratory services; the Company's proposed transaction with DataVault AI Inc. (NASDAQ:DVLT), Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.
INVESTOR CONTACT Investor Relations | ir@datamedsai.com
MEDIA CONTACT James Lambert, Vice President, Rubenstein Public Relations jlambert@rubensteinpr.com 212-805-3024
SOURCE: DataMEDS AI, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is DataMEDS AI planning for the Health Lives Here application?
DataMEDS AI plans to launch the Health Lives Here consumer application, with management stating they intend to soft launch the app in the near term as they promote the broader DataMEDS story to the market.
How does DataMEDS AI describe its business model and technology stack?
DataMEDS AI describes itself as a Health IT company focused on vertically integrating technology, pharmacy, pharmaceutical‑adjacent, and telemedicine business units to improve the consumer healthcare experience. The company incorporates its EinsteinRx™ AI platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application, while its Corexa Health subsidiary provides pharmacy services and distributes products developed by Tollo Health, LLC.
What branding purpose does the new corporate website serve for DataMEDS AI?
The company states that the new corporate website reflects the parent company's new branding and supports a retooled, AI‑centric marketing effort aimed at generating organic online traction and earned media interest.